2017
Current and Emerging Drug Therapies in Chronic Lymphocytic Leukemia
Sethi T, Reddy N. Current and Emerging Drug Therapies in Chronic Lymphocytic Leukemia. TouchREVIEWS In Oncology & Haematology 2017, 13: 34. DOI: 10.17925/ohr.2017.13.01.34.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsB cell receptorDrug therapyCLL therapyChronic lymphocytic leukemia patientsElderly unfit patientsAdditional treatment optionsDuration of treatmentRepertoire of drugsImmune effector responsesLymphocytic leukemia patientsChronic lymphocytic leukemiaLong-term toxicityUnfit patientsPatient ageCD20 antibodyRisk stratificationCLL treatmentAsymptomatic individualsTherapy optionsTreatment optionsEffector responsesLeukemia patientsLymphocytic leukemiaCLL cellsTreatment approaches
2015
Ibrutinib in chronic lymphocytic leukemia
Reddy N, Sethi T. Ibrutinib in chronic lymphocytic leukemia. International Journal Of Hematologic Oncology 2015, 4: 143-150. DOI: 10.2217/ijh.15.15.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsB cell receptorTyrosine kinaseKey survival pathwaysMalignant B cellsSignal transductionKinase pathwayBruton's tyrosine kinaseSurvival pathwaysCell survivalSignal triggersB cellsPathwayChronic lymphocytic leukemiaB cell proliferationKey roleTumor microenvironmentTumor malignancyCellsTransductionKinaseLymphocytic leukemia